Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

New genetic discoveries and treatment for hepatitis C.

Pacanowski M, Amur S, Zineh I.

JAMA. 2012 May 9;307(18):1921-2. doi: 10.1001/jama.2012.3516. No abstract available.

PMID:
22570460
2.

Genetic factors and hepatitis C virus infection.

Thompson AJ.

Gastroenterology. 2012 May;142(6):1335-9. doi: 10.1053/j.gastro.2012.01.046. No abstract available.

PMID:
22537440
3.

Role of interleukin-28B polymorphism as a predictor of sustained virological response in patients with chronic hepatitis C treated with triple therapy: a systematic review and meta-analysis.

Bota S, Sporea I, Şirli R, Neghină AM, Popescu A, Străin M.

Clin Drug Investig. 2013 May;33(5):325-31. doi: 10.1007/s40261-013-0074-0. Review.

PMID:
23532802
4.

Boceprevir for chronic HCV genotype 1 infection.

Hsu CS, Kao JH.

N Engl J Med. 2011 Jul 14;365(2):176-7; author reply 177-8. doi: 10.1056/NEJMc1105515#SA2. No abstract available.

PMID:
21751913
5.

Interferon stimulated genes and hepatitis C virus infection.

Asselah T.

J Interferon Cytokine Res. 2012 Dec;32(12):557-62. doi: 10.1089/jir.2012.0059. Epub 2012 Nov 14. Review.

PMID:
23151203
6.

IL28B: A new wager in the skyline of hepatitis C virus infection.

Mangia A.

Dig Liver Dis. 2011 Mar;43(3):177-9. doi: 10.1016/j.dld.2010.12.005. Epub 2011 Jan 14. No abstract available.

PMID:
21237729
7.
8.

New protease inhibitors and direct-acting antivirals for hepatitis C: interferon's long goodbye.

Dusheiko G, Wedemeyer H.

Gut. 2012 Dec;61(12):1647-52. doi: 10.1136/gutjnl-2012-302910. Epub 2012 Aug 30. No abstract available.

PMID:
22936671
9.

Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4.

Ragheb MM, Nemr NA, Kishk RM, Mandour MF, Abdou MM, Matsuura K, Watanabe T, Tanaka Y.

Liver Int. 2014 Jul;34(6):890-5. doi: 10.1111/liv.12321. Epub 2013 Oct 14.

PMID:
24102823
10.

Boceprevir for chronic HCV genotype 1 infection.

Limaye AR, Draganov PV, Cabrera R.

N Engl J Med. 2011 Jul 14;365(2):176; author reply 177-8. doi: 10.1056/NEJMc1105515#SA1. No abstract available.

PMID:
21751914
11.

Clinical utility of interleukin-28B testing in patients with genotype 1.

Lai M, Afdhal NH.

Hepatology. 2012 Jul;56(1):367-72. doi: 10.1002/hep.25793. Review. No abstract available.

PMID:
22511388
12.

Genomic variation-guided management in chronic hepatitis C.

Hsu CS, Kao JH.

Expert Rev Gastroenterol Hepatol. 2012 Aug;6(4):497-506. doi: 10.1586/egh.12.24. Review.

PMID:
22928901
13.

[Chronic hepatitis C: improved cure rates with new approved medications].

Grammatikos G, Vermehren J, Zeuzem S.

MMW Fortschr Med. 2012 Jun 21;O 154 Suppl 2:65-9; quiz 70. Review. German. No abstract available.

PMID:
22916428
14.

Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.

Itokawa N, Atsukawa M, Tsubota A, Kondo C, Hashimoto S, Fukuda T, Matsushita Y, Kidokoro H, Kobayashi T, Narahara Y, Nakatsuka K, Kanazawa H, Iwakiri K, Sakamoto C.

J Gastroenterol Hepatol. 2013 Mar;28(3):443-9. doi: 10.1111/jgh.12039.

PMID:
23173698
15.

The Effects of IL-28B and ITPA polymorphisms on treatment of hepatitis C virus genotype 6.

Seto WK, Tanaka Y, Liu K, Lai CL, Yuen MF.

Am J Gastroenterol. 2011 May;106(5):1007-8. doi: 10.1038/ajg.2011.40. No abstract available.

PMID:
21540909
16.

An overview of emerging therapies for the treatment of chronic hepatitis C.

Ilyas JA, Vierling JM.

Clin Liver Dis. 2011 Aug;15(3):515-36. doi: 10.1016/j.cld.2011.05.002. Review.

PMID:
21867934
17.

Interleukin-28B genetic variations and response to interferon-based therapy: Asian perspectives.

Liu CH, Kao JH.

J Gastroenterol Hepatol. 2011 Sep;26(9):1348-53. doi: 10.1111/j.1440-1746.2011.06842.x. No abstract available.

PMID:
21884245
18.

Toward the establishment of a prediction system for the personalized treatment of chronic hepatitis C.

Ochi H, Hayes CN, Abe H, Hayashida Y, Uchiyama T, Kamatani N, Nakamura Y, Chayama K.

J Infect Dis. 2012 Jan 15;205(2):204-10. doi: 10.1093/infdis/jir726. Epub 2011 Nov 28.

PMID:
22124128
19.

Antiviral combination therapy with peginterferon and ribavirin does not induce a therapeutically resistant mutation in the HCV core region regardless of genetic polymorphism near the IL28B gene.

Toyoda H, Kumada T, Hayashi K, Honda T, Katano Y, Goto H, Kawaguchi T, Murakami Y, Matsuda F.

J Med Virol. 2011 Sep;83(9):1559-64. doi: 10.1002/jmv.22145.

PMID:
21739446
20.

Comment on: 'interleukin-28 polymorphisms on the SVR in the treatment of naïve chronic hepatitis C with pegylated interferon-α plus ribavirin: a meta-analysis'.

Fernández-Rodríguez A, Jiménez-Sousa MÁ, Resino S.

Gene. 2013 Jun 10;522(1):121. doi: 10.1016/j.gene.2013.03.013. Epub 2013 Mar 16. No abstract available.

PMID:
23506831

Supplemental Content

Support Center